Heterogeneity in the responsiveness to long-term lifestyle intervention and predictability in obese women with polycystic ovary syndrome

European Journal of Endocrinology

Volumn 164, Issue 1, 2011, Pages 53-60

  Pasquali, Renato ^a   Gambineri, Alessandra ^a   Cavazza, Carla ^a   Gasparini, Daniela Ibarra ^a   Ciampaglia, Walter ^b   Cognigni, Graciela Estela ^b   Pagotto, Uberto ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b Day Surgery Center   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROSTENEDIONE; GLUCOSE; INSULIN;

ADULT; ANDROSTENEDIONE BLOOD LEVEL; ANTHROPOMETRIC PARAMETERS; ANTHROPOMETRY; ARTICLE; CALORIC RESTRICTION; CLINICAL EVALUATION; CONTROLLED STUDY; DIET RESTRICTION; DIETARY INTAKE; FEMALE; FOLLOW UP; HUMAN; INSULIN RESISTANCE; LABORATORY TEST; LIFESTYLE MODIFICATION; MAJOR CLINICAL STUDY; METABOLIC PARAMETERS; OBESITY; OUTCOME ASSESSMENT; OVARY POLYCYSTIC DISEASE; OVULATION; PHYSICAL ACTIVITY; PRIORITY JOURNAL; WAIST CIRCUMFERENCE; WAIST HIP RATIO; WEIGHT REDUCTION; ANDROGEN BLOOD LEVEL; HYPERANDROGENISM; INTERVENTION STUDY; LONG TERM CARE; MENSTRUATION DISORDER; OVARY INSUFFICIENCY; PROGNOSIS; TREATMENT RESPONSE;

ADULT; AGED; ANDROSTENEDIONE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INSULIN RESISTANCE; INTRA-ABDOMINAL FAT; LOGISTIC MODELS; MIDDLE AGED; OBESITY; POLYCYSTIC OVARY SYNDROME; PREDICTIVE VALUE OF TESTS; RISK REDUCTION BEHAVIOR; WEIGHT LOSS;

EID: 78751510733     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-10-0692     Document Type: Article

References (30)

1. Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar- Morreale HF, Futterweit W, Janssen OE, Legro RS, Norman RJ, Taylor AE, Witchel SF & Androgen Excess Society. Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. Journal of Clinical Endocrinology and Metabolism 2006 91 4237-4245. (doi:10.1210/jc.2006-0178) (Pubitemid 44833391)
2. The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Human Reproduction 2004 19 41-47. (doi:10.1093/humrep/deh098)
3. Gambineri A, Pelusi C, Vicennati V, Pagotto U & Pasquali R. Obesity and the polycystic ovary syndrome. International Journal of Obesity and Related Metabolic Disorders 2002 26 883-896. (doi:10.1038/sj.ijo.0801994)
4. Pasquali R. Obesity and androgens: facts and perspectives. Fertility and Sterility 2006 85 1319-1340. (doi:10.1016/j.fertnstert.2005.10.054)
5. Ehrmann DA. Polycystic ovary syndrome. New England Journal of Medicine 2005 352 1223-1236. (doi:10.1056/NEJMra041536)
6. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanisms and implications for pathogenesis. Endocrine Reviews 1997 18 774-800. (doi:10.1210/er.18.6.774)
7. Legro RS. Polycystic ovary syndrome and cardiovascular disease: a premature association? Endocrine Reviews 2003 24 302-312. (doi:10.1210/er.2003- 0004)
8. Shaw LJ, Bairey Merz CN, Azziz R, Stanczyk FZ, Sopko G, Braunstein GD, Kelsey SF, Kip KE, Cooper-Dehoff RM, Johnson BD, Vaccarino V, Reis SE, Bittner V, Hodgson TK, Rogers W & Pepine CJ. Postmenopausal women with a history of irregular menses and elevated androgen measurements at high risk for worsening cardiovascular event-free survival: results from the National Institutes of Health - National Heart, Lung, and Blood Institute sponsored Women's Ischemia Syndrome Evaluation. Journal of Clinical Endocrinology and Metabolism 2008 93 1276-1284. (doi:10.1210/jc.2007-0425)
9. Moran LJ, Pasquali R, Teede HJ, Hoeger KM & Norman RJ. Treatment of obesity in polycystic ovary syndrome: a position statement of the Androgen Excess and Polycystic Ovary Syndrome Society. Fertility and Sterility 2009 92 1966-1982. (doi:10.1016/j.fertnstert.2008.09.018)
10. Zawadzki JK & Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rationale approach. In Polycystic Ovary Syndrome, pp 377-384. Eds A Dunaif, JR Givens, FP Haseltine & GR Merriam. Boston, MA: Blackwell Scientific Publications, 1992.
11. Ferriman D & Gallwey JD. Clinical assessment of body hair growth in women. Journal of Clinical Endocrinology and Metabolism 1961 21 1440-1447. (doi:10.1210/jcem-21-11-1440)
12. Pasquali R, Patton L, Pocognoli P, Cognigni GE & Gambineri A. 17-Hydroxyprogesterone responses to gonadotropin-releasing hormone disclose distinct phenotypes of functional ovarian hyperandrogenism and polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 2007 92 4208-4217. (doi:10.1210/jc.2007-0870)
13. Vermeulen A, Verdonck L & Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. Journal of Clinical Endocrinology and Metabolism 1999 84 3666-3672. (doi:10.1210/jc.84.10.3666) (Pubitemid 30645223)
14. Matthews DR, Hosker JP, Rudenski AS, Nylor BA, Treacher DF & Turner RC. Homeostasis model assessment: insulin resistance and b-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985 28 412-419. (doi:10.1007/BF00280883)
15. Mather KJ, Hunt AE, Steinberg HO, Paradisi G, Hook G, Katz A, Quon MJ & Baron AD. Repeatability characteristic of simple indices of insulin resistance: implications for research applications. Journal of Clinical Endocrinology and Metabolism 2001 86 5457-5464. (doi:10.1210/jc.86.11.5457)
16. Matsuda M & De Fronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing. Diabetes Care 1999 22 1462-1470. (doi:10.2337/diacare.22.9.1462)
17. Escobar-Morreale HF, Botella-Carretero JI, Alvarez-Blasco F, Sancho J & San Millan JL. The polycystic ovary syndrome associated with morbid obesity may resolve after weight loss induced by bariatric surgery. Journal of Clinical Endocrinology and Metabolism 2005 90 6364-6369. (doi:10.1210/jc.2005- 1490)
18. Moghetti P, Castello R, Negri C, Tosi F, Perrone F, Caputo M, Zanolin E & Muggeo M. Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebocontrolled 6-month trial, followed by open, long-term clinical evaluation. Journal of Clinical Endocrinology and Metabolism 2000 85 139-146. (doi:10.1210/jc.85.1.139) (Pubitemid 32268804)
19. Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar- Morreale HF, Futterweit W, Janssen OE, Legro RS, Norman RJ, Taylor AE, Witchel SF & Task Force on the Phenotype of the Polycystic Ovary Syndrome of the Androgen Excess and PCOS Society. The Androgen Excess and PCOS Society Criteria for the polycystic ovary syndrome: the complete task force report. Fertility and Sterility 2009 91 456-488. (doi:10.1016/j.fertnstert.2008.06.035)
20. Stener-Victorin E, Holm G, Nilsson L, Janson PO & Ohlson C. Are there any sensitive and specific sex steroid markers for polycystic ovary syndrome? Journal of Clinical Endocrinology and Metabolism 2009 95 810-819. (doi:10.1210/jc.2009-1908)
21. Loughlin T, Cunningham SK, Culliton M, Smyth PP, Meagher DJ & McKenna TJ. Altered androstenedione and estrone dynamics associated with abnormal hormonal profiles in amenorrheic subjects with weight loss or obesity. Fertility and Sterility 1985 43 720-725.
22. Xita N, Georgiou I, Lazaros L, Psofaki V, Kolios G & Tsatsoulis A. The synergistic effect of sex hormone-binding globulin and aromatase genes on polycystic ovary syndrome phenotype. European Journal of Endocrinology 2008 158 861-865. (doi:10.1530/EJE-07-0905)
23. Pasquali R, Casimirri F, Venturoli S, Morselli Labate AM, Reho S, Pezzoli A & Paradisi R. Body fat distribution has weight-independent effects on clinical, hormonal, and metabolic features of women with polycystic ovary syndrome. Metabolism 1994 43 706-713. (doi:10.1016/0026-0495(94)90118-X) (Pubitemid 24181196)
24. Blouin K, Boivin A & Tchernof A. Androgens and body fat distribution. Journal of Steroid Biochemistry and Molecular Biology 2008 108 272-280. (doi:10.1016/j.jsbmb.2007.09.001)
25. van Dam EW, Roelfsema F, Veldhuis JD, Hogendoorn S,Westenberg J, Helmerhorst FM, Frölich M, Krans HM, Meinders AE & Pijl H. Retention of estradiol negative feedback relationship to LH predicts ovulation in response to caloric restriction and weight loss in obese patients with polycystic ovary syndrome. American Journal of Physiology. Endocrinology and Metabolism 2004 286 E615-E620. (doi:10.1152/ajpendo.00377.2003)
26. Palomba S, Falbo A, Zullo F & Orio F Jr. Evidence-based and potential benefits of metformin in the polycystic ovary syndrome: a comprehensive review. Endocrine Reviews 2009 30 1-50. (doi:10.1210/er.2008-0030)
27. Dunaif A & Thomas A. Current concepts in the polycystic ovary syndrome. Annual Review of Medicine 2001 52 401-419. (doi:10.1146/annurev.med. 52.1.401)
28. Willis DS, Watson H, Mason HD, Galea R, Brincat M & Franks S. Premature response to luteinizing hormone of granulosa cells from anovulatory women with polycystic ovary syndrome: relevance to mechanism of anovulation. Journal of Clinical Endocrinology and Metabolism 1998 83 3984-3991. (doi:10.1210/jc.83.11.3984)
29. Zhang G, Garnay JC & Verdhuis JD. Interactive stimulation by luteinizing hormone and insulin of the steroidogenetic acute regulatory (StAR) protein and 17α-hydroxylase/17,20 lyase (CYP17) genes in porcine theca cells. Endocrinology 2000 141 2735-2742. (doi:10.1210/en.141.8.2735)
30. Pasquali R & Gambineri A. Obesity and the polycystic ovary syndrome: a cause-effect relationship? Obesity and Metabolism 2008 4 177-182.